Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene

Annals of Hematology

Volumn 94, Issue 11, 2015, Pages 1927-1928

  Rumi, Elisa ^a   Milosevic, Jelena D ^b   Selleslag, Dominik ^c   Casetti, Ilaria ^d   Lierman, Els ^e   Pietra, Daniela ^a   Cavalloni, Chiara ^d   Bellini, Marta ^d   Milanesi, Chiara ^a   Dambruoso, Irene ^a   Astori, Cesare ^a   Kralovics, Robert ^b,f   Vandenberghe, Peter ^e   Cazzola, Mario ^a,d  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c AZ Sint Jan   (Belgium)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RUXOLITINIB; ONCOPROTEIN; PCM1-JAK2 FUSION PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

ADULT; AGED; ANEMIA; CANCER REGRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; EOSINOPHILIC LEUKEMIA; FEMALE; FOLLOW UP; FUSION GENE; HUMAN; LETTER; MALE; MYELOPROLIFERATIVE NEOPLASM; PCM1 AK2 FUSION GENE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; GENETICS; HYPEREOSINOPHILIC SYNDROME; MYELOPROLIFERATIVE DISORDERS; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PYRAZOLES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84941994977     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2451-7     Document Type: Letter

References (3)

1. Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, Tapper W, Score J, Waghorn K, Naumann N, Jawhar M, Fabarius A, Hofmann WK, Cross NC, Reiter A (2015) Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol 94(2):233–8
2. Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P (2012) Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 120(7):1529–31
3. Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, Boni M, Bernasconi P, Passamonti F, Kralovics R, Cazzola M (2013) Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol 31(17):e269–71